TherapeuticsMD, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
TherapeuticsMD, Inc. (TXMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.00 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2023-04-07.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-04-07
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was -59.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-09-30 was 0.00 shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-06-30 was 311.50K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-03-31 was 919.50K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 1.00K shares, a 99.86% decline from fiscal 2020.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 737.00K shares, a 84.05% decline from fiscal 2019.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 4.62M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2021-12-31 | -59.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-07 | 1.00K shares 10-K · filed 2023-04-07 | 60.00K shares 10-K · filed 2022-03-23 | ||
| 2021-09-30 | 60.00K shares 10-Q · filed 2021-11-12 | ||||
| 2020-12-31 | 737.00K shares 10-K · filed 2022-03-23 | 736.50K shares 10-K · filed 2021-03-04 | |||
| 2019-12-31 | 4.62M shares 10-K · filed 2022-03-23 | ||||
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 311.50K shares derived: sum of 2 quarters · filed 2015-11-05 | 1.23M shares 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | 311.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | 1.23M shares 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | 919.50K shares 10-Q · filed 2015-05-07 | ||||
| 2014-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 50.00K shares 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | 50.00K shares 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |